Fidelity and Privacy of
Synthetic Medical Data
Review of Methods and Experimental Results
June 2021

Ofer Mendelevitch, Michael D. Lesh SM MD FACC,
Keywords: synthetic data; statistical fidelity; safety; privacy; data access; data sharing; open data;
metrics; EMR; EHR; clinical trials; review of methods; de-identification; re-identification; deep learning;
generative models

1

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Table of Contents
Table of Contents

2

Abstract

3

1. Introduction
1.1 De-Identification and Re-Identification
1.2 Synthetic Data

3
3
4

2. Synthetic Data in Medicine
2.1 The Syntegra Synthetic Data Engine and Medical Mind

5
6

3. Statistical Fidelity Validation
3.1 Record Distance Metric
3.2 Visualize and Compare Datasets
3.3 Population Statistics
3.4 Single Variable (Marginal) Distributions
3.5 Pairwise Correlation
3.6 Multivariate Metrics
3.6.1 Predictive Model Performance
3.6.2 Survival Analysis
3.6.3 Discriminator AUC
3.7 Clinical Consistency Assessment

6
6
7
8
9
10
11
11
12
13
13

4. Privacy Validation
4.1 Disclosure Metrics
4.1.1 Membership Inference Test
4.1.2 File Membership Hypothesis Test
4.1.3 Attribute Inference Test
4.2 Copy Protection Metrics
4.2.1 Distance to Closest Record - DCR
4.2.2 Exposure

13
13
14
16
16
17
17
18

5. Experimental Results
5.1 Datasets
5.2 Results
5.2.1 Statistical Fidelity
5.2.2 Privacy

19
19
20
20
30

6. Discussion and Analysis
6.1 DIG dataset results analysis
6.2 NIS dataset results analysis
6.3 TEXAS dataset results analysis
6.4 BREAST results analysis

34
34
35
35
36

7. Conclusions

36

References

38

2

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Abstract
The digitization of medical records ushered in a new era of big data to clinical science, and with it the
possibility that data could be shared, to multiply insights beyond what investigators could abstract from
paper records. The need to share individual-level medical data to accelerate innovation in precision
medicine continues to grow, and has never been more urgent, as scientists grapple with the COVID-19
pandemic. However, enthusiasm for the use of big data has been tempered by a fully appropriate
concern for patient autonomy and privacy. That is, the ability to extract private or confidential
information about an individual, in practice, renders it difficult to share data, since significant
infrastructure and data governance must be established before data can be shared. Although HIPAA
provided de-identification as an approved mechanism for data sharing, linkage attacks were identified
as a major vulnerability. A variety of mechanisms have been established to avoid leaking private
information, such as field suppression or abstraction, strictly limiting the amount of information that can
be shared, or employing mathematical techniques such as differential privacy. Another approach,
which we focus on here, is creating synthetic data that mimics the underlying data. For synthetic data
to be a useful mechanism in support of medical innovation and a proxy for real-world evidence, one
must demonstrate two properties of the synthetic dataset: (1) any analysis on the real data must be
matched by analysis of the synthetic data (statistical fidelity) and (2) the synthetic data must preserve
privacy, with minimal risk of re-identification (privacy guarantee). In this paper we propose a framework
for quantifying the statistical fidelity and privacy preservation properties of synthetic datasets and
demonstrate these metrics for synthetic data generated by Syntegra technology.
Keywords: synthetic data; statistical fidelity; safety; privacy; data access; data sharing; open data;
metrics; EMR; EHR; clinical trials; review of methods; de-identification; re-identification; deep learning;
generative models

1. Introduction
A prerequisite to healthcare innovation is the availability of high-quality, unbiased, and diverse patient-level
medical datasets. Increasingly, patient data from patient care and clinical trials or an increasing number of
commercial data sources (for example, there is now a wealth of general consumer data as well as specific
health-related data from wearable devices and fitness apps) are being generated by providers, governments,
industry and individuals themselves. While such datasets can be a rich resource for investigators in those
organizations, they are generally not accessible to the broader research community due to patient privacy
concerns. Even when it is possible for a researcher to gain access to such data, ensuring proper governance and
complying with strict legal requirements is a lengthy and expensive process. This can severely hamper the
timeliness of research and, consequently, its translational benefits to patient care. This delay is particularly
devastating now, during the rapidly advancing COVID-19 pandemic.
As noted in [1], â€œsharing data produced from clinical trials...has the potential to advance scientific discovery,
improve clinical care, and increase knowledge gained from data collected in these trials. As such, data sharing
has become an ethical and scientific imperative.â€ Unfortunately, this ethical mandate may conflict with the equally
important ethical and legal mandate to protect patient privacy, and the reality is that data owners are reluctant to
share patient level medical datasets. And even with these restrictions, â€œdata sharingâ€ as described in the
academic literature generally applies to credentialed academic researchers collaborating with other academic
investigators, or life-sciences industries who can provide large research grants to those academics.
As discussed in Section 1.1 below, methods of de-identification that are based on HIPAAâ€™s safe-harbor provisions
([2]), first established by law in 1996, are much less effective now, considering the vulnerability to linkage attacks combining â€œde-identifiedâ€ data with information available elsewhere, such as social media or public records, to
extract highly sensitive personal information ([3], [4]). At the same time, they may also significantly degrade the
utility of the data [25].

1.1 De-Identification and Re-Identification
As detailed in [5], the simplest method of privacy protection is to remove all fields (HIPAA prescribed 18 such
fields) that could directly and uniquely identify an individual, such as name, social security number, and phone
3

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

number. Until the mid 2000s, this was considered adequate to de-identify data, and pursuant to the HIPAA
Privacy Rule 45 CFR 164 such data no longer constitutes protected health information (PHI). The assumption
was that once these 18 types of information were removed or masked, and the disclosing entity had no actual
knowledge that the information in the de-identified dataset could be used to identify an individual, the disclosure
did not constitute a significant risk to privacy. However, in recent years, it became clear that many other data fields
can be used to identify individuals [4].
GDPR expands the scope of protected information beyond PHI, instead using the term â€œpersonal data,â€ where
â€œpersonal dataâ€ means any information relating to an identified or identifiable natural person (â€œdata subjectâ€),
whereas HIPAA is limited to information generated by healthcare providers, insurers and clearinghouses and
pertaining to the medical treatment of patients. An identifiable natural person is one who can be identified, directly
or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an
online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic,
cultural or social identity of that natural person.
Moreover, GDPR distinguishes two types of de-identification: pseudonymization and anonymization.
Pseudonymized data may in many cases be similar to de-identified data under HIPAA, but contrary to HIPAA
which explicitly does not apply to de-identified data, GDPR still imposes legal restrictions on pseudonymized data,
albeit less stringent ones than for fully identifiable data. For example, data containing an encrypted patient key
could potentially still be rendered de-identified under HIPAA, provided only the data source, but not the data
recipient can decrypt this key or otherwise use it to recover the patientâ€™s identity, whereas under GDPR such data
would only be pseudonymized, and GDPR would continue to apply. Full anonymization pursuant to GDPR is
defined such that even if the identified source data or any other auxiliary data (whether or not available to the data
recipient), could be used to recover patient identity; it is, however, difficult to achieve and retains very little
analytic utility. Thus, in order to be able to use GDPR protected data, significant legal burdens will typically have
to be met, and this can be especially challenging for entities outside the EU. Importantly, defining â€œidentifiableâ€
data is complicated by the possibility of re-identification [6]. Re-identification is the matching of anonymized data
back to an individual. In recent years, faith that de-identification prevents re-identification can no longer be
supported. For example, a 2009 Social Security Number study [7] showed that data about an individual's place
and date of birth, voter registration, and other publicly available information can be used to predict their Social
Security number.
Traditional techniques for disclosure limitation can be classified in a number of ways, grouped by information
limiting methods and data perturbation methods. Information limiting methods are those that delete, mask,
suppress, or obscure data fields or values in order to prevent re-identification. Data perturbation methods are
those that use statistical means to alter the underlying data itself, by adding noise and/or limit the query results
that can be drawn from the data.

1.2 Synthetic Data
In this paper, we will focus on the use of synthetic medical data, a novel method for data sharing that does not
explicitly limit or perturb data, and instead learns a high granularity statistical representation from the data in order
to generate completely synthetic medical records using sampling and randomization. This in principle can provide
high statistical fidelity and low risk of disclosure.
Given the stakes in healthcare, when claims are made that any particular method renders a dataset
non-re-identifiable, there must be a set of metrics to ensure that such a claim is warranted. In general, there is a
tradeoff between the risk of disclosure and the utility of a disclosed dataset - the higher the utility, the lower the
level of privacy guarantee, and vice-versa, as shown in figure 1:

4

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 1: trade-off between utility and privacy
Different disclosure techniques represent different trade-off curves; for example, information-limiting techniques
are often more detrimental to utility than perturbation techniques, whereas synthetic data (if done properly) can
provide the best trade-off.
Therefore, it is essential to develop a set of metrics and associated acceptance criteria that can be used to
determine when synthetic data can be trusted to provide real world evidence. Of course, any real-world dataset
from which an investigator hopes to draw conclusions based on a statistical analysis, is itself a sample of a much
larger universe. In other words, our expectation that the synthetic dataset matches the real dataset is really a
proxy for the expectation that the synthetic dataset and real dataset are both samples from the same underlying
distribution. As an example, suppose we have a dataset of 1000 patients with coronary heart disease, 500 of
whom have had treatment X and 500 have been treated with a placebo. The outcome is that treatment X is
significantly better than placebo. A clinician or a regulatory body has enough assurance that they are willing to
recommend treatment X for all qualifying patients with heart disease, acknowledging that those 1000 patients are
a representative sample of say 19,000,000 Americans with coronary heart disease. Taken together, the fidelity
metrics suggested in this paper provide a high level of assurance that the real dataset and synthetic dataset are
drawn from the same distribution.
In fact, we may find that synthetic data is actually a better representation of the ground truth. That is because
creation of the synthetic dataset may in some cases remove out of distribution anomalies. The synthetic data
engine could have an error filtering function that is not present when the real dataset is used directly in statistical
analyses.
We present here a collection of metrics and visualizations to assess the privacy and fidelity claims of any method
for synthetic data generation, and the method of synthetic medical data generation in particular. In section 2 we
provide a brief overview of synthetic data generation in healthcare. In section 3 and 4 we describe our proposed
framework for evaluating statistical fidelity of synthetic data against the real data and measuring privacy and
disclosure risk. In section 5 we present experimental results with four datasets, using Syntegraâ€™s generative
engine, in section 6 we analyze our results, and in section 7 we present our conclusions.

2. Synthetic Data in Medicine
Synthetic data has been used in a number of applications, such as computer vision and robotics [8], and creating
synthetic controls for economics and social sciences [9], where randomized trials are not possible, but a
comparison to an intervention is required. The privacy preserving properties of synthetic data has been initially
discussed in [10], and much later in [11] and [21].
For reducing the risk of patient data re-identification and accelerating the process by which such data is made
more widely available, synthetically generated data is a promising alternative or addition to standard
anonymization procedures. Some mechanisms of creating synthetic data do so based on simulating disease
processes, known patterns of care, or disease-specific guidelines (notably [12] and [13]), which means starting
with heuristics about medical conditions, such as practice guidelines or literature review, and letting rules drive
new record production. These methods typically fail to anticipate unusual edge cases, such as surgical
complications, other adverse events or rare conditions, which means that they fail to satisfy the needs of modern
precision medicine. For regulatory approval or post-approval vigilance of therapeutics that require real world data,
5

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

and where synthetic data will substitute for the actual data because of privacy concerns, the synthetic data should
be created from the data itself [14], i.e., data-driven synthesis as opposed to process- or rule-based simulation.
Indeed, outside of pedagogical or population-based modeling, synthetic data has seen limited use in
mission-critical applications such as synthetic control groups in clinical trials to support regulatory approval or
post-approval surveillance.

2.1 The Syntegra Synthetic Data Engine and Medical Mind
At Syntegra, we have developed a novel machine-learning-based synthetic data generator, the Syntegra Medical
Mind, that can convert any type of clinical data into an equivalent synthetic version. The patient-level data can be
from any real-world database (RWD), or from observational or prospective clinical trials. The synthetic dataset is
intended to match the statistical properties of the original, while providing strong privacy protection, as validated
by the metrics defined below. Note that rather than providing only aggregate statistics, the synthetic data is
created at the level of individual participants. The goal is a dataset that mimics the statistical properties of the real
data and can be used for any analysis, including training-state-of-the-art, predictive models like random forest or
gradient boosted trees, with performance that matches that of models trained on the original data.
Unlike many previous synthetic data techniques that add noise or attempt to simulate results based on
hand-coded rules or guidelines, our method is data-centric: it uses a very large neural network to learn, in an
unsupervised fashion, the underlying probability distribution in the real data. A synthetic dataset is then generated
that accurately maintains the statistical properties of the real data, while preserving privacy. The engine works by
viewing all the data points for a given participant as a "patient sentence", with events in time or tabular data, and
learning the underlying latent probability distribution by training a language models1 on those â€œsentences'';
subsequently, the trained model can be used to generate synthetic sentences by sampling from the learned
distribution (which is encoded by the neural network). By repeating that process any number of times, we
generate a set of patient-level clinical records. Utilizing transfer learning, our generative model leverages a
pre-trained corpus that is fine-tuned, in an unsupervised fashion, by the real dataset that one wants converted into
a synthetic equivalent. The pre-trained corpus contains a representation of medical patterns extracted from
general and health-care related data, augmented by new datasets as they are encountered. That is, the Syntegra
Medical Mind improves over time as each new set of real data enriches the pre-trained corpus.

3. Statistical Fidelity Validation
Given a real medical dataset R, and a synthetic dataset S generated based on R, our goal is to measure the
statistical fidelity between R and S. But what do we mean by the term â€œstatistical fidelityâ€?
Here, we explore six methods to compare the degree to which the synthetic dataset is an accurate replica of the
original dataset:
1) Visualize the real and synthetic datasets using dimensionality reduction
2) Compare summary statistics
3) Compare single variable distributions
4) Compare pairwise correlations
5) Multivariate and non-linear metrics
6) Clinical consistency check on the synthetic data
As demonstrated by the famous Anscombeâ€™s quartet [15] example - statistical metrics have known limitations,
which proper visualization can sometimes help address. Thus, in our framework for statistical fidelity we use a
combination of visualization and metrics, recognizing that good metrics provide an easy numerical value by which
to judge fidelity comparing real to synthetic data, whereas visualization provides a more nuanced view of
differences.

3.1 Record Distance Metric
Some statistical fidelity and privacy tests require a reasonable measure of distance between each pair of records.
Some common distance functions are Euclidean distance, cosine distance, Gower distance, or Hamming
distance; many others exist - see e.g. [17]). With healthcare data it is important to provide a true distance metric2
that appropriately deals with both numeric and categorical values, as well as missing values.

1

2

https://openai.com/blog/better-language-models/
A true distance metric is symmetric and satisfies the triangle inequality, with each item having distance 0 to itself.

6

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Here we describe two possible choices for a distance metric. The first one is Gower distance, which was first
described in [30] and is common for data with mixed (both numeric and categorical) variables, and a robust
extension of Gower distance, replacing normalized manhattan distance with a variant of wave-hedges is
described in [29].
Given two vectors xi and xj, both with dimension p, the enhanced gower distance is defined as:
ğ‘

(

)

Eq (1): ğ‘‘ğº ğ‘¥ğ‘–, ğ‘¥ğ‘— =

âˆ‘ ğ‘¤ğ‘–ğ‘—ğ‘šğ‘‘ğ‘–ğ‘—ğ‘š

ğ‘š=1
ğ‘

âˆ‘ ğ‘¤ğ‘–ğ‘—ğ‘š

ğ‘š=1

where ğ‘‘ğ‘–ğ‘—ğ‘š is the distance between the m-th variable of x and y, and ğ‘¤ğ‘–ğ‘—ğ‘šis an optional weighting for each variable.
In this paper we use ğ‘¤ğ‘–ğ‘—ğ‘š = 1 for all variables, but we note that an interesting alternative to consider is weighting
variables by their relative importance in the use of the distance metric.
Based on combining [29] and [30] we define the individual distance for a given variable as follows:
â—

For categorical variables: ğ‘‘ğ‘–ğ‘—ğ‘š = {

0, ğ‘“ğ‘œğ‘Ÿ ğ‘¥ğ‘– = ğ‘¥ğ‘—
1, ğ‘“ğ‘œğ‘Ÿ ğ‘¥ğ‘– â‰  ğ‘¥ğ‘—
1+ğ‘šğ‘–ğ‘›(ğ‘¥ , ğ‘¥ )

â—

For numerical variables, ğ‘‘ğ‘–ğ‘—ğ‘š = {

1âˆ’ 1+ğ‘šğ‘ğ‘¥(ğ‘¥ğ‘– , ğ‘¥ğ‘— ) ,
ğ‘–

ğ‘“ğ‘œğ‘Ÿ ğ‘šğ‘–ğ‘›(ğ‘¥ğ‘–, ğ‘¥ğ‘—)â‰¥0

ğ‘—

1

1âˆ’ 1+ğ‘šğ‘ğ‘¥(ğ‘¥ , ğ‘¥ )+ ğ‘šğ‘–ğ‘›(ğ‘¥ , ğ‘¥ ) ,
ğ‘–

ğ‘—

|

ğ‘–

ğ‘—

|

ğ‘“ğ‘œğ‘Ÿ ğ‘šğ‘–ğ‘›(ğ‘¥ğ‘–, ğ‘¥ğ‘—)<0

An alternative approach, which weâ€™ve used to report the results in sections 4 and 5 below, is to bucket numeric
values into percentile bins, and in that way transform them into categorical variables. The distance computation in
this case remains the same, and we only have categorical variables.
Lastly, to deal properly with missing values, we use the following approach:
â— For categorical values, we define a â€œmissing valueâ€ as a separate (additional) category
â— For numerical values, we define ğ‘‘ğ‘–ğ‘—ğ‘š = 1if one of xim or xjm is missing but the other is not, and as 0 if both
are missing.

3.2 Visualize and Compare Datasets
Before diving into numerical analysis, it is an accepted data science methodology first to visualize datasets,
especially where one wishes to compare two datasets, and where the number of records is large. Graphical
visualization makes use of humanâ€™s innate ability to recognize patterns, concordance, and deviation. However,
given that a medical dataset can be of very high dimensionality, with heterogeneous data types, it can be a
challenge to create a visualization that is coherent to a human observer. Recently, robust dimensionality
reduction methods such as tSNE and UMAP [22] were introduced. UMAP seeks to learn the manifold structure of
a dataset and find a low dimensional embedding that preserves the essential topological structure of that
manifold.
In Figure 2a, each point represents a dimensionally reduced single patient record from a high-dimensional
medical dataset. The axes themselves have no convenient interpretation, but the clustering present in the data is
clear in the visualization. Figure 2a shows the full UMAP scatter plot of the whole datasets, whereas figure 2b
zooms in on a specific small cluster of points in more detail.

7

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 2a: UMAP visualization of a clinical trial dataset. On left, the real dataset; on right, the synthetic dataset.

Figure 2b: UMAP visualization of a clinical trial dataset - small cluster of patient records (zoomed in) - real data
on the left, synthetic data on the right
Undoubtedly, some records are close to others, hence clustering on multiple scales is noted. Some records are
â€œedge casesâ€ and represent small groups far from the centroid (red circles). Note that the coverage of the
synthetic dataset (figure 2a - right) is quite an accurate representation of the distribution of the real data (figure 2a
- left), including covering the edge cases. This is important, as simple numerical analysis may show that the
synthetic and real data have similar central tendency, which might miss a failure of the synthetic dataset to
replicate the small cohorts or edge cases present in the real data. The distribution of real and synthetic points is
ideally close but should not be identical. That is, the synthetic data should not be just a copy of the real. Larger
magnification reveals that they are not identical, and our privacy metrics (see section 4) prove that copying has
not taken place.
By using UMAP, we can clearly see that even small cohorts are picked up in the synthetic data. Another reason
small cohort coverage is important is that standard de-identification methods, such as for HIPAA compliant
de-identification, often require removal of small cohorts out of concern for re-identification via membership
inference. So, a truly robust synthetic data engine will maintain these small cohorts, while still maintaining privacy.

3.3 Population Statistics
The next step in validation that should be performed when presented with any new dataset is summary statistics
or population statistics [16]. The difference in our case is that these summary statistics will be computed in a
paired fashion on the real and then on the synthetic data, and then compared. Table 1a provides an example for
numeric variables, where we compare the mean and standard deviation for real vs synthetic, whereas table 1b
provides an example for categorical variables, where we compare the count and percentage in each category:

Numeric variables
variable

Real
mean

Categorical variables
Synthetic

SD

mean

SD

variable

Value

Real

Synthetic

8

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

AGE

55.4

8.8

55.3

8.9

BMI

24.3

4.9

24.5

5.0

HEIGHT

170.1

22.1

171.2

21.9

WEIGHT

82.9

23.5

83.2

23.5

Table 1a

n
SEX
RACE

%

n

%

Female

1,519

22.3

1634

24.0

Male

5,281

77.7

5166

76.0

991

14.6

1073

15.8

5809

85.4

5727

84.2

NonWhite
White

Table 1b
The goal of this exercise is to understand whether population-level statistics on the real data match those of the
synthetic data.

3.4 Single Variable (Marginal) Distributions
Moving from variable-level statistics to distributions we compare the distribution of a given variable in the real data
to its distribution in the synthetic data. For numeric variables, the distributions can be easily compared using a
histogram:

Figures 3a and 3b: Histogram comparing similar (left) and differing (right) distributions of numeric variables
The (non-parametric) 2-sided KS-statistic3 can be used as a statistical test to determine whether the two variables
(real vs. synthetic) are drawn from the same distribution. The KS-statistic is a value between 0 and 1; when this
value is small (or the associated p-value is high, above 0.05), then we cannot reject the null hypothesis that the
distribution of the real variable is the same as that of the synthetic variable, which means there is high statistical
fidelity of synthetic data when compared to real data.
For the example in figure 3a above, the KS-statistic value is 0.0126 and the p-value is 0.405, clearly consistent
with a good fit. Figure 3b demonstrates the opposite case where the two distributions donâ€™t match -In this case the
KS-statistic value is 0.392 and the p-value<0.0001, again consistent with our expectations of a poor fit.
For categorical variables, the category-based histogram is a useful visualization tool to understand differences in
distribution:

Figures 4a and 4b: Histogram comparing similar (left) and differing (right) distributions of categorical variables
The Kullbackâ€“Leibler (KL) divergence is a measure of how one probability distribution diverges from a second
expected probability distribution, and it is often used to compare two categorical distributions. The closer the KL
divergence is to 0, the more similar the distributions. In figure 4a, the KL divergence is 0.0062, suggesting a close
match between the distributions. In the distribution shown in Figure 4b, the KL divergence is 0.2645, consistent
with a mismatch between the distributions.

3

Note that other statistical metrics, such as chi-squared test for independence, are also acceptable

9

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Another interesting metric for comparing individual categorical variables is support coverage, as defined in [17],
which measures how much of the variableâ€™s support (number of unique categorical values or levels) in the real
data is covered in the synthetic data. Concretely, support coverage is defined as:

(

)

Eq (2): ğ‘† ğ‘‹ğ‘…, ğ‘‹ğ‘† =
ğ‘£

1
ğ‘‰

ğ‘‰

ğ‘£

ğ‘†
âˆ‘ | ğ‘‰|

| |

ğ‘£=1 ğ‘…
ğ‘£

Where ğ‘† represents the cardinality of synthetic variable v, and ğ‘… represents the cardinality of real variable v, and
V is the set of all categorical variables. A high support coverage value reflects better coverage of categorical
levels in the synthetic data and thus higher fidelity.
Yet another option here is wasserstein distance4 (also known as â€œearth-moverâ€™sâ€ distance) which is often used
instead of KL-divergence.

3.5 Pairwise Correlation
Univariate metrics do not describe interactions between variables. It is useful therefore to measure the pairwise
correlation5 between some or all pairs of variables in the dataset; if the pairwise correlation of the synthetic data is
similar to that in the real data, then statistical fidelity is maintained.

Figure 5a: Pairwise correlation heatmap - high fidelity
Figure 5a compares the correlation heatmap generated with the real data (left) against the same heatmap
generated with the synthetic data (right) and is helpful in understanding the degree to which pairwise correlations
between each pair of variables are maintained. The variables included in the heatmap are a choice of the
evaluator. If the number of variables is small, all variables can be included. If the number of variables exceeds
what can be understandably displayed, one can include the N most common variables in the dataset, variables of
clinical importance, or use some other criteria to select these variables. It can be of interest to compare relatively
uncommon variables in the heatmap to see how well the synthetic engine handles rare conditions or edge cases
present in the real dataset.

Figure 5b: Pairwise correlation heatmap - low fidelity

4
5

https://en.wikipedia.org/wiki/Wasserstein_metric
Herein we use Pearson correlation, but other forms of correlation (e.g. Spearman or Kendall) are equally valuable

10

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 5b demonstrates low fidelity between the real and synthetic data. Pairwise correlation can be measured
quantitatively with the pairwise correlation difference (PCD), computed as the L1 or L2 norm of the difference
between the correlation matrices:
Eq (3a): ğ‘ƒğ¶ğ·ğ¿1 = ||ğ¶ğ‘œğ‘Ÿğ‘Ÿ(ğ‘Ÿğ‘’ğ‘ğ‘™) âˆ’ ğ¶ğ‘œğ‘Ÿğ‘Ÿ(ğ‘ ğ‘¦ğ‘›)||1
Eq (3b): ğ‘ƒğ¶ğ·ğ¿2 = ||ğ¶ğ‘œğ‘Ÿğ‘Ÿ(ğ‘Ÿğ‘’ğ‘ğ‘™) âˆ’ ğ¶ğ‘œğ‘Ÿğ‘Ÿ(ğ‘ ğ‘¦ğ‘›)||2

Where Corr(real) represents the correlation matrix for the real data, and Corr(syn) is the same for synthetic data.
PCD values of 0 or close to 0 coincide with the synthetic data being closer to the real data, and higher values
mean less statistical fidelity. The highest value of PCD is 1. For example, in figure 5a, the PCD-L1 is 0.007
whereas for figure 5b, the PCD-L1 is 0.17, consistent with our expectations.

3.6 Multivariate Metrics
Although relatively simple to visualize and understand, both single variable and pairwise fidelity metrics lack the
ability to evaluate the statistical fidelity from a perspective that takes into account all the variables and their
granular linear and non-linear interactions. To address this, we propose three multivariate metrics: (1) predictive
model performance (2) survival analysis (3) discriminator AUC / pMSE.

3.6.1 Predictive Model Performance
An effective form of fidelity validation works as follows: train two instances of a machine learning model (using a
commonly accepted algorithm such as a linear regression, random forest, gradient boosted trees, or a deep
neural network) - one trained with real data, and the other trained with synthetic data; then compare the predictive
performance of the models on a real-data validation set. Using a modern predictive modeling algorithm, we can
gain insight into data fidelity at the multivariate level since the models exploit non-linearities and multivariate
correlations in the predictive variables.
If the target variable for the predictive model is a binary variable (classification), a common and widely used
metric for measuring the performance of the predictive models is the area-under-the-curve of the
receiver-operator-characteristic (ROC-AUC)6. Additional metrics such as accuracy, precision, recall and F1 are
also informative, but to avoid too many metrics we recommend choosing only the relevant ones for the use case
at hand. The ratio of the synthetic ROC-AUC and the real ROC-AUC becomes the quality metric for statistical
fidelity, with higher values representing better statistical fidelity. The higher this ratio, the better the fidelity of
synthetic data with the real.
If the target variable for the predictive model is a continuous variable, common and widely used metrics of
performance are RMSE (root-mean-squared-error) and MAE (mean-absolute-error).
For predictive models with binary targets, we can visualize the modelsâ€™ performance through the ROC curve, and
calculate the ratio in ROC-AUC between the model based on real data vs. the model based on synthetic data.
With high fidelity synthetic data, we expect the ROC and corresponding AUC of the synthetic data to be close to
each other.

6

https://en.wikipedia.org/wiki/Receiver_operating_characteristic
Note that ROC-AUC is equivalent to another statistics commonly used to summarize the ROC curve - the C-statistic.

11

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figures 6a and 6b: ROC AUC metrics comparing two predictive models with high (left) and low (right) fidelity
In figure 6a we see an example of two predictive models (generated using gradient boosted trees) where the
ROC curves of the two models are nearly identical, and the AUC metrics are within a margin of error. This reflects
very good fidelity of the synthetic data with the real data. In figure 6b we see the opposite case where the fidelity
between the two datasets is low, resulting in the ROC curve of synthetic data closer to the red line (representing
random decision).
When using predictive model performance to compare synthetic to real datasets, it is important to ensure proper
data science hygiene principles:
â— Use models that provide the best predictive performance. For example, in many real-world scenarios
linear models underperform more advanced modeling techniques such as gradient boosted trees or
random forest.
â— Always set aside a separate validation set from the real dataset and evaluate performance of the
predictive models on that validation set for both real and synthetic cases.
â— Use hyperparameter tuning to ensure the compared models are fully optimized.
â— Run the predictive model multiple times with different randomizations to ensure the outcome is not due to
chance.
In practical use, the predicted variable would be one of clinical significance to the dataset being considered. For
example, for general hospitalized patients, length-of-stay and readmission risk might be relevant, whereas for
patients with severe COVID-19, the outcomes might be risk of admission to the ICU, risk of intubation, length of
time on a ventilator, and risk of death. It is also important that there are no variables used in the prediction that
leak, or anticipate, the predicted variable. For example, the lab test â€œtype and cross for blood transfusionâ€ would
be inappropriate to use as a predictor of â€œlikelihood of surgery in the next week.â€
Model performance analysis pertains to the synthetic data engine and says nothing about how useful or accurate
the predictions. For example, there may be independent variables missing from the original dataset that materially
impact the outcome. In predicting death due to COVID-19, unless every patient's resuscitation status is included
in the input data, a predictor of death will severely underperform. Patients with â€œdo not resuscitate" orders are
much more likely to die then a patient with all other features matched, but without such an order. If a â€œdo not
resuscitateâ€ order is absent from the features of the predictive model, the model will fail. The synthetic engine will
generate a dataset equivalent to the real dataset, and the output (ROC curve) using the real and synthetic data
will match, but the generative model has no way to know that a critical variable was not included.
When comparing predictive models trained on real vs synthetic data, it is useful to evaluate the â€œfeature
importanceâ€ from these models and compare the most important features between the real and synthetic
datasets. Predictive models are increasingly coming under scrutiny, requiring interpretation of the model output to
open up the black-box risk in such models. It follows that if a synthetic data set is an accurate representation of a
real data set, the interpretation of a predictive model trained using real and using synthetic data should be very
close. A leading method for computing feature importance is Shapley values (SHAP7) [24], which we use in our
experiments and evaluation. Aside from the visualization of SHAP values, we use nDCG8 (normalized discounted
cumulative gain) to compare the ranking of feature importances and summarize the difference in a single metric;
we donâ€™t expect feature rankings between real and synthetic to match exactly as small changes in training
algorithms can result in minor changes in feature importance, but we do expect them to be very similar, with an
nDCG value close to 1.0.

3.6.2 Survival Analysis
Survival analysis provides a statistical framework to analyze time-to-event outcomes. To understand whether the
characteristics of time-to-event are maintained in the synthetic data, we perform Kaplan-Meier9 analysis on the
real data and then compare analysis on the synthetic data when there is a temporal aspect of the real data. In
addition to the visualization of Kaplan-Meier curves, we use the p-value from the analysis as a metric to compare
real data to synthetic data. Of course other types of survival analysis such as Cox Regression can be used to
compare real data to synthetic data.

7

An alternative is to use LIME - https://homes.cs.washington.edu/~marcotcr/blog/lime/
https://en.wikipedia.org/wiki/Discounted_cumulative_gain
9
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059453/
8

12

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

3.6.3 Discriminator AUC
Inspired by generative adversarial networks10, Another metric for multivariate fidelity is the â€œdiscriminator AUCâ€.
Specifically, we build a classification model trained to discriminate between the real data records and the synthetic
ones. Using ROC-AUC as a measure of performance for this discriminator model, a synthetic dataset with high
statistical fidelity to the real dataset will result in a ROC-AUC value for this discriminator model that is close to 0.5
(representing random decision classifier), whereas low fidelity synthetic data are reflected with ROC-AUC values
closer to 1. As described above with predictive models, itâ€™s important to use a strong modeling technique and run
the discriminative model multiple times with different randomizations to ensure the outcome is not due to chance.
The propensity-score mean squared error (pMSE) is a variant of ROC-AUC described in [18]. Similar to
discriminator AUC, we build a discriminator model, and estimate the propensity of each record to be real or
synthetic. The metric is then defined as the mean-squared-error between the propensity scores and the actual:
ğ‘

(

ğ¸ğ‘ (4): ğ‘ğ‘€ğ‘†ğ¸ = âˆ‘ ğ‘ğ‘– âˆ’ ğ‘
ğ‘–=1

)

Where pi represents the propensity score for record i, and c is the proportion of synthetic records in the training
set for the discriminator. We expect low pMSE (close to 0) for a synthetic dataset with high statistical fidelity to the
real.

3.7 Clinical Consistency Assessment
In synthetic medical data, a final metric of fidelity for synthetic data is based on domain expertise that validates
the data quality. We apply rules generated by clinicians or scientists to identify inconsistencies in the data that
represent failed synthetic data generation, for example:
1.
2.
3.
4.

Patient is male and pregnant
Patient is female and has been diagnosed with prostate cancer
Patient is age 0-3, with adult demographics such as weight > 100 lbs, height > 5 feet, etc.
Patient is listed as dead, at time T but has clinical events at time T* > T

Given a library of rules, we calculate the number of records with inconsistencies as a percentage of the overall
number of records.

4. Privacy Validation
One of the primary goals of using synthetic data is to prevent disclosure of private patient information.
We evaluate synthetic data privacy as follows:
â— Disclosure metrics: understanding how much disclosure risk may result from access to the synthetic
dataset.
â— Copy protection metrics: demonstrating that records from the real dataset are not â€œcopied overâ€ to the
synthetic dataset.
We assume that direct identifiers (such as first name, last name, address or social security number) are always
removed from the real data before it is being used to generate synthetic data. This is often already the case for
the source data, with commonly used de-identification software and/or service can be applied to achieve this
initial state.
In the following we use the following notation:
â— R represents the dataset of real records, and S represents the synthetic dataset
â— Q is a set of quasi-identifier fields that are used by a potential attacker to match records, such as age,
gender, ethnicity, zip code or similar.

4.1 Disclosure Metrics
There are two forms of disclosure used in classical statistical disclosure practice (not related specifically to
synthetic data): identity disclosure and information disclosure. Identity disclosure is the discovery of the identity of
10

https://arxiv.org/abs/1406.2661

13

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

the subject of a disclosed record, whereas information disclosure is the discovery of (additional) information about
a known subject. Identity disclosure usually leads to information disclosure (once the subject of a record is
identified, the record provides additional, potentially sensitive information about that individual, such as medical or
psychiatric conditions, HIV status, etc.), so classical disclosure limitation aims to prevent identity disclosure, and
the HIPAA Privacy Rule is explicitly framed in this way.
We do note that information disclosure can happen without identity disclosure, in real datasets. For example, if a
de-identified dataset contains a 3-digit ZIP code and the age and gender of patients (something generally
permitted under HIPAA) and it is known from general census data that there are five individuals of a given age
and gender in a certain 3-digit ZIP code, and the de-identified data contains five distinct individuals all of whom
have diabetes, then the user of the de-identified data can deduce that the five individuals in that age/gender/ZIP
code bucket whose identities may be found in voter registries, consumer data etc., are all diabetics, even if it is
still not known how to match the de-identified records to the known identities. For handling real data, whether or
not such disclosures are acceptable, needs some careful consideration. In this instance it may be undesirable, but
in other cases such disclosure may only include general statistical information that can be disclosed. It is often
challenging to carry out a systematic analysis of such disclosure, and this is another advantage of synthetic data.
For synthetic data, the concept of identity disclosure is somewhat ill-defined. In any meaningful application of data
synthesis, where records are generated from a distribution, there is by construction no connection between a
given synthetic record and any unique individual.
What is true for synthetic datasets (as well as for classically de-identified datasets) is that there can be no
prohibited disclosure of identity or information about an individual, if no data associated with this individual is used
in the construction of the data. Thus, a de-identified dataset will not violate the privacy of a patient not
represented in the data, and a synthetic dataset will not do so if no information associated with the individual was
used to train the synthetic algorithm. The only information about an individual that could be leaked from a
synthetic dataset created without the use of that patientâ€™s true data is general statistical information that we do not
aim to conceal. For example, if a synthetic dataset reveals that all patients who have an appendectomy performed
have been diagnosed with appendicitis, and the user of that synthetic dataset concludes that their work colleague
who mentioned having had their appendix removed must have had such a diagnosis, this would not be an
illegitimate information disclosure.
Thus, to understand disclosure risk for synthetic data we focus on membership inference and attribute inference
attacks. In a membership inference attack the adversary aims to identify the participation of a known patient
record in the training of the synthetic generation algorithm, and in an attribute inference attack the adversary
attempts to infer values of one or more sensitive attributes from the synthetic dataset.

4.1.1 Membership Inference Test
Membership inference attacks seek to infer membership of a patient record in the real dataset from which the
synthetic data was generated. For example, if the training set used to train a generative model consists of HIV
positive patient records (e.g., the HIV status is not included as a field, but it is a clinical study of HIV patients),
then inferring whether a patient record was included in that training will reveal that that patient is HIV positive.
We now describe a validation test for membership inference on synthetic data. Following [21] let R be a (large)
training set of real patient data, and ğ‘Ÿâˆˆğ‘… a patient record. For simplicity of presentation, we assume that R
contains one unique record per patient, though this limitation can be easily removed. We split the training data
randomly into two disjoint subsets of equal size, ğ‘… = ğ‘…1 âˆª ğ‘…2 . We train the generative model on ğ‘…1 and generate
a synthetic data set ğ‘†1. We utilize a reasonable measure of distance between the source patient record r and any
synthetic record s, such as the one described in 3.1.
Even though there is no well-defined concept of the â€œidentity of a synthetic recordâ€, we can design a well-defined
test for â€œmembership inferenceâ€. Concretely, we consider a hypothetical adversary which has access to a subset
of records in R which we denote ğ‘…3 (note that records in ğ‘…3 may belong to either ğ‘…1 and ğ‘…2), and that attempts a
membership inference â€œattackâ€ as follows:

14

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

â—

Given a patient record ğ‘Ÿâˆˆğ‘…3 , and the disclosed synthetic dataset ğ‘†1, the adversary identifies the closest
record ğ‘  âˆˆ ğ‘†1 with distance ğ‘‘(ğ‘Ÿ, ğ‘  ).

â—

The adversary determines that ğ‘Ÿ is part of the training set of ğ‘†1 if ğ‘‘(ğ‘Ÿ, ğ‘ ) is lower than some threshold
chosen by the adversary (in our simulation we use the minimum Hamming distance that provides a
match H, H+1, H+2, H+3, and H+5).

We want to evaluate the success rate of such an adversarial strategy. For each record ğ‘Ÿâˆˆğ‘…3 we know if it actually
belongs to ğ‘…1 or ğ‘…2, and can then determine whether the adversaryâ€™s decision constitutes a true positive, true
negative, false positive or false negative, and measure the confusion matrix. We then compute precision11 and
recall and plot them as a function of the % of records in R that are present in ğ‘…3.
Figure 7a describes in a visual form the approach for the membership inference attack:

Figure 7a: membership inference diagram
Precision represents the number of correct decisions the adversary has made; since we randomly split R into ğ‘…1
and ğ‘…2 with equal sizes, the baseline precision is 0.5 (corresponding to random choice), and any value above that
reflects increasing levels of disclosure risk (or increased risk of success for the membership inference attack).
Recall (aka sensitivity) represents the percent of records known to an attacker that can be found in the training
set. Clearly as the Hamming distance threshold increases (and recall increases), the attacker identifies more and
more such records as belonging to the training set (although that doesnâ€™t mean such identification is correct as
reflected in the precision). This is demonstrated in figure 7b below:

11

https://en.wikipedia.org/wiki/Precision_and_recall

15

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 7b: membership inference metrics
As can be seen in this example, the precision of membership inference attack is very close to the baseline of 0.5
and thus represents minimal risk of disclosure. From the example in Figure 7b, it is clear that no matter the
threshold chosen by the adversary (Hamming distance threshold chosen, reflected in the recall), the likelihood of
making a correct membership inference metric is very close to â€œrandom guessâ€.
As a summary metric, we look at the precision of membership inference at the first threshold reflecting recall level
of 50% or higher (in figure 7b above hamming distance <= 20), normalized to a value between 0 and 1
ğ‘€ğ¼ ğ‘…ğ‘–ğ‘ ğ‘˜ ğ‘†ğ‘ğ‘œğ‘Ÿğ‘’ = (ğ‘ğ‘Ÿğ‘’ğ‘ğ‘–ğ‘ ğ‘–ğ‘œğ‘› âˆ’ 0. 5) * 2
We consider MI Risk score < 0.2 (20%) as very low risk of disclosure due to membership inference.

4.1.2 File Membership Hypothesis Test
We now present a slight variant of the membership inference test, where we perform a random membership
inference test N times, and use statistical hypothesis testing to gain insight into possible success of a membership
inference attack. In a similar manner to 4.1.1, we split the training data randomly into two disjoint subsets of equal
size, ğ‘… = ğ‘…1 âˆª ğ‘…2. We then train the generative model on ğ‘…1 to generate a synthetic data set ğ‘†1, and train the
generative model on ğ‘…2 to generate a synthetic data set ğ‘†2. For any patient record ğ‘Ÿâˆˆğ‘…, we find the closest
records ğ‘ 1 âˆˆ ğ‘†1 and ğ‘ 2 âˆˆ ğ‘†2. If ğ‘‘(ğ‘Ÿ, ğ‘ 1) < ğ‘‘(ğ‘Ÿ, ğ‘ 2) we say r is in S1, and otherwise r is in S2. We deem this
determination to be correct if ğ‘Ÿâˆˆğ‘†1 and false otherwise.
Running this process N times, each time performing the randomization using a different random seed, we can
perform hypothesis testing. Let P be the probability that our test is â€œcorrectâ€, or experimentally the rate of â€œcorrectâ€
answers over a large sample. We then make the null hypothesis H0: ğ‘ƒâ‰ 1/2. Using standard Central Limit
Theorem methods we can then aim to reject H0. If we succeed in doing so, this is a powerful indication of privacy.
It states that we are unable to guess with any greater accuracy than a coin toss whether a patientâ€™s records were
even present in the data used to train a model. This precludes any identity or information disclosure.
We consider the synthetic dataset S to represent very low disclosure risk if we are able to reject the null
hypothesis (p-value<0.05).

4.1.3 Attribute Inference Test
Following [21] and [27] we split the dataset variables into two subset: (1) Q (quasi-identifiers, e.g. age, gender or
race) which is a subset of variables in the dataset that the attacker may possess about real patients and (2) the
rest of the variables, including some sensitive variables the attacker may try to infer.
For a specific person, the attacker obtains a given set of values of the quasi-identifier variables Q, and filters the
synthetic dataset to those records that match the quasi-identifiers (ğ‘†ğ‘); by default an exact match is performed to
16

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

establish Sq but an approximate match can also be performed whereby a row in S is matched for each field in Q
within a certain range of values around the exact values obtained by the attacker. Now with ğ‘†ğ‘ the attacker infers
the value of the sensitive variable t for that person as follows:
1. If t is categorical, the attacker selects the mode of ğ‘†ğ‘(ğ‘¡) as the inferred value
2.

If t is numeric, the attacker computes the median of ğ‘†ğ‘(ğ‘¡) as the inferred value

Alternatively the attacker can train a machine-learning model (such as a random forest or gradient boosted trees
model) using the synthetic dataset S as a training set (where the quasi-identifiers Q are used as predictors and
the sensitive variable t is used as the target) and then predict the value of t using this model.
In our evaluation we follow [27] and estimate the disclosure risk for a sensitive variable t as follows:
Eq (6): ğ‘‘ğ‘–ğ‘ ğ‘ğ‘™ğ‘œğ‘ ğ‘¢ğ‘Ÿğ‘’ ğ‘Ÿğ‘–ğ‘ ğ‘˜(ğ‘¡)
Where
â—

=

1
ğ‘›ğ‘ 

ğ‘›ğ‘ 

âˆ‘

(

ğ‘ =1

1
ğ‘“ğ‘ 

)

'

Â· Î»ğ‘  Â· ğ¼ğ‘  Â· ğ‘…ğ‘ 

ğ‘›ğ‘ is the number of records in the real dataset

â—

ğ‘“ğ‘ is the equivalence class size in the real sample for particular records s in that real sample

â—

Î»ğ‘ is the adjustment factor due to errors in matching; in [27] the authors use Î»

â—

where k is the number of quasi-identifier fields (see that paper for more details).
ğ¼ğ‘ is an indicator variable that takes a value of 1 if the record s in the real data has a matching record in

â—

the synthetic data, and 0 otherwise
ğ‘…ğ‘ is an indicator variable that takes a value of 1 if the adversary would learn something new from

'

'

ğ‘ 

ğ‘˜

=

1+(0.23ğ‘¥(1âˆ’0.0426)
2

matching the records s to the synthetic data
This disclosure risk represents the percentage of records which, for this sensitive variable t, represent high risk of
disclosure. We consider a disclosure risk of 0.05 (5%) or lower to be very low and acceptable for practical
purposes.
Our methodology closely follows [27], however with a few improvements:
â— For each variable <t> not included in the Quasi-identifiers, we compute and report the disclosure risk for
this variable as specified above. We consider the overall disclosure risk for a patient record as the
maximum disclosure risk for that patient record across all variables (as opposed to [27] where they
consider a patient record at risk if L% of variables are at risk of disclosure).
â— We use Jenks Natural Breaks to bin numeric values into K bins (as a more robust approach to using
k-means clustering suggested in [27]); we estimate the optimal value of K by calculating goodness-of-fit
and picking the first K where itâ€™s above 0.8.
â— Missing values are considered lower risk, if disclosed. By default, we reduce the risk by 50%, and this
can be configured manually as part of risk assessment. This weighting is associated with Rs, reflecting
the fact that a missing value discloses less â€œnew informationâ€ if missing.
â—

'

We note that the definition of Î»ğ‘  is based on field experience and other peer reviewed studies as
described in [27] and they provide a strong baseline; we also recommend and implement two other
variants that represents stronger privacy guarantees: (1) a more conservative estimate of 80% match
rate and 0% error rate (2) a no-error estimate of 100% match rate and 0% error rate.

We report for each target variable the disclosure risk as computed above, and exemplified in table 2:
Target Variable
Reference paper
Conservative
No Errors

COVID+
0.00234
0.00534
0.00662

HIV+
0.0234
0.0266
0.0345

Diabetic
0.000012
0.00003
0.00043

Total
0.00243
0.00331
0.00532

Table 2: Example attribute inference results for three sensitive variables: COVID+, HIV+ and diabetic. We report
three variants of the disclosure risk: using the error estimate used in [27], a more conservative estimate, and the
most conservative (no errors) estimate.

17

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Although not reported in our results here, we note a possible future enhancement where a â€œsensitivity weightâ€ is
associated with each variable, and the disclosure risk is properly adjusted accordingly. For example, any
disclosure associated with a variable about COVID positive status or HIV positive status is more sensitive than
disclosure of a patientâ€™s height or age.

4.2 Copy Protection Metrics
An important question when looking at high fidelity synthetic data that is derived from real data is â€œhow do I know
that the synthetic data is not a simple copy or minor perturbation of the original real dataâ€, resulting in high risk of
disclosure?
To address this issue, we propose two methods:
â— Distance-to-closest-record (or DCR)
â— Exposure to unintended memorization

4.2.1 Distance to Closest Record - DCR
For any given real patient record ğ‘Ÿâˆˆğ‘… we define DCR(r) as the distance between r and that record in the synthetic
dataset ğ‘ âˆˆğ‘† that is closest to it. Assuming an appropriate distance metric d(r,s) as discussed in 3.1, to compute
the DCR for a given record ğ‘Ÿ in the real dataset we take the minimal distance to all candidate records in the
synthetic dataset ğ‘ ğ‘— and obtain that rowâ€™s DCR value.
Eq (7): ğ·ğ¶ğ‘…(ğ‘Ÿ) = ğ‘šğ‘–ğ‘›ğ‘— ğ‘‘(ğ‘Ÿ, ğ‘ ğ‘—)
The intuition here is that DCR provides us with an understanding of the distance between records in the real and
synthetic datasets, and any situation where exact copies or simple perturbations of the real records that exist in
the synthetic dataset will be easily exposed by the DCR metric.
Figure 8a demonstrates a privacy-preserving synthetic dataset where DCR values are â€œfarâ€ from 0, whereas figure
8b demonstrates a situation where some synthetic records exactly match the real records, while some other do
not, which represents a high risk of unintended copying of at least some of the records (those with DCR=0).

Figures 8a and 8b: DCR distribution example: privacy preserving synthetic dataset (left) and synthetic data
containing many copies of the original (right).
For privacy-preserving synthetic data we expect DCR between the real dataset and the synthetic dataset
(real-synthetic) look like figure 8a where the lowest DCR value is far from 0, and not like figure 8b where we see a
large number of exact copies of real records that have an exact match in the synthetic dataset.
We note, however, that although visualizing the DCR distribution in this way provides useful insights into privacy
preservation, DCR=0 in itself doesnâ€™t necessarily map to high disclosure risk - in some datasets the â€œspaceâ€
spanned by the variables in scope is relatively small. As an extreme example, if we only have 3 variables: gender
(with values male/female), Race (with values White or Non-White) and COVID-positive (with values 0 or 1), then
there are exactly 8 possible records and any dataset with more than 8 records would have at least 2 records that
are exactly the same (DCR=0). Therefore, we propose the following metric to estimate disclosure risk for records
with DCR=0:

18

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

1.

We call ğ‘…0 the subset of real records records with DCR=0.

2.

For all records in ğ‘…0, we calculate all the possible equivalence classes and consider those with an
equivalence class (in R) size of 5 or less as â€œhigh risk rowsâ€ - ğ‘…ğ»ğ‘….

3.

We consider a synthetic dataset risk disclosure low when the percent of high risk rows out of the overall
dataset - computed as |ğ‘…ğ»ğ‘…| / |R| - is less than 1%, following industry best practices in re-identification
analysis.

4.2.2 Exposure
Our second copy protection test is specific to synthetic data engines that can associate a probability to any given
record (or sample) ğ‘ƒ(ğ‘Ÿğ‘’ğ‘ğ‘œğ‘Ÿğ‘‘), representing how likely that record is to occur in the synthetic dataset; as has been
recently demonstrated in [20] and [26], this is useful in order to assess whether or not a synthetic data generator
might be unintentionally memorizing the input data.
Following [20] we propose to measure the extent of unintended memorization by injecting â€œcanary samplesâ€
(values far outside the distribution of real data) into the training set and measuring log-perplexity (defined as
ğ‘™ğ‘œğ‘”(ğ‘ƒ(ğ‘ ğ‘ğ‘šğ‘ğ‘™ğ‘’))) and exposure in the synthetic dataset. Specifically, for a given synthetic dataset generated using
a synthetic engine, we define for a given canary record c injected into the training data the exposure as:
Eq (8): ğ‘’ğ‘¥ğ‘ğ‘œğ‘ ğ‘¢ğ‘Ÿğ‘’(ğ‘) = ğ‘™ğ‘œğ‘”2(|ğ¶|) âˆ’ ğ‘™ğ‘œğ‘”2(ğ‘Ÿğ‘ğ‘›ğ‘˜(ğ‘))
Where rank(c) is the rank of the chosen canary amongst all possible canaries and C is the space of all possible
canaries. Exposure is a real value ranging between 0 and ğ‘™ğ‘œğ‘”2(|ğ¶|); its maximum can be achieved only by the
most-likely, top-ranked canary; conversely, its minimum of 0 is the least likely; across possibly inserted canaries,
the median exposure is 1.
Thus, our proposed metric works as follows:
â— Insert N randomly chosen canaries into the training set R, resulting in Râ€™ (original R + the canaries)
â— Generate a synthetic dataset Sâ€™ from Râ€™
â— Calculate the average exposure over the N canaries in Sâ€™
By estimating the size of C, we can calculate the â€œextraction thresholdâ€ as ğ‘™ğ‘œğ‘”2(|ğ¶|) and measure the exposure
level against that threshold. If the actual exposure is lower than the threshold, we determine that the risk of
unintended memorization is low, whereas if the exposure is higher than the threshold then the risk is high.
Note that this method requires access to the synthetic data generation engine (as opposed to just access to a
given synthetic dataset), as the canaries need to be included in the training dataset.

5. Experimental Results
We evaluate our fidelity and safety metrics with four datasets, which we abbreviate as: DIG, NIS, TEXAS, and
BREAST. For each dataset, we generate synthetic data using Syntegraâ€™s engine, and compute the fidelity and
privacy validation metrics. Note that for some metrics, like ML modeling ROC-AUC or discriminator AUC we
actually ran this evaluation 5 times, each time generating synthetic data using a different randomization seed, and
measured the metrics in each case, using mean and std-deviation to report the average and standard-deviation of
each metric.

5.1 Datasets
The Digitalis Investigation Group (DIG) study [31] was a randomized, double-blind, multicenter trial with more than
300 centers in the United States and Canada. The purpose of the trial was to examine the safety and efficacy of
digoxin in treating patients with congestive heart failure (CHF), in sinus rhythm, with an ejection fraction â‰¤ 0.45.
Endpoints were mortality from any cause (the primary endpoint) and hospitalization for heart failure (the
secondary end point) over a three-to-five-year period. We downloaded openly available, participant-level data
from the NIH/NHLBI BioLINCC data repository. This dataset includes 6,800 patient records and 71 variables, and
we generated a dataset of 20,000 synthetic patient records.

19

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

The National Inpatient Sample database12 (NIS) is a patient-level administrative claims database that represents
approximately 20% of discharges from US community hospitals. The NIS includes data on patient demographics,
primary and secondary diagnoses, medical comorbidities, surgical procedures, length of stay, and discharge
disposition. We utilized a version of this dataset with 116,009 patient records and 31 variables and generated a
dataset with 200,000 synthetic patient records.
The TEXAS Hospital Discharge dataset13 is a large public use data file provided by the Texas Department of State
Health Services. The dataset we used consists of 50,000 records uniformly sampled from a pre-processed data
file that contains records from 2013, similar to how it is used in [23], retaining the same 18 data attributes (of
which 11 are categorical and 7 continuous attributes). We generated a dataset with 100,000 synthetic patient
records.
The National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) collects cancer
incidence data from population-based cancer registries covering approximately 35 percent of the U.S. population.
The SEER registries collect data on patient demographics, primary tumor site, tumor morphology, stage at
diagnosis, and first course of treatment, and they follow up with patients for vital status. We used the portion of
the SEER dataset comprised of breast cancer patient records, taken from the SEER Incidence database14, and
which consists of 1,072,173 patient records with 117 variables including demographics, cancer diagnosis and
classification, and other related fields. We generated a dataset with 1,500,000 synthetic patient records.
Table 3 below summarizes the characteristics of all the datasets included in our study:
Dataset
DIG
NIS
TEXAS
BREAST

Rows in original data
Columns
6,800
71
116,009
31
50,000
18
1,072,173
117

Rows generated
20,000
200,000
100,000
1,500,000

Table 3: dataset characteristics summary

5.2 Results
In this section we describe our experimental results. In most cases we compare the original dataset to the full
synthetic dataset (which is often generated with a larger number of records), except when specifically mentioned.

5.2.1 Statistical Fidelity
First, we look at population statistics for each dataset, comparing real to synthetic for selected variables in each
dataset. We randomly sample the synthetic dataset to the same size as the original. The results are demonstrated
in tables 4a-4d below:
Numeric variables
variable
AGE
BMI
HEART_RATE
EJF_PER

Real
mean
SD
63.5
10.9
27.1
5.2
78.8
12.7
28.5
8.8

Categorical variables

Synthetic
mean
SD
63.2
10.8
27.3
5.2
78.6
12.6
28.6
8.9

variable
SEX
RACE
FUNCTCLS

Val
Female
Male
NonWhite
White
Class I
Class II
Class III
Class IV

Real
n
1,519
5,281
991
5,809
907
3,664
2,081
142

%
22.3
77.7
14.6
85.4
13.3
53.9
30.6
2.1

Synthetic
n
%
1,476
21.7
5,324
78.3
1,018
15.0
5,782
85.0
913
13.4
3,653
53.7
2,081
30.6
148
2.2

Table 4a: DIG - population statistics - example numeric and categorical variables
Numeric variables
variable
age
Length of stay

Real
mean
66.6
7.5

Categorical variables
Synthetic

SD
13.7
9.2

mean
66.4
7.4

SD
13.8
9.8

variable
Major
amputation

Val
No

Real
n
105,251

Synthetic
%
90.7

n
105,053

%
90.6

12

https://www.hcup-us.ahrq.gov/nisoverview.jsp
https://www.dshs.texas.gov/thcic/hospitals/UserManual1Q2013.pdf
14
https://seer.cancer.gov/data/
13

20

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Sex

10,757
67,114
48,892

Yes
male
female

9.3
57.9
42.1

10,955
66,131
49,876

9.4
57.0
43.0

Table 4b: NIS - population statistics - example numeric and categorical variables
Categorical variables

Numeric variables
variable

Real

Total charges ($)
Total charges
accomod ($)
Length of stay

Synthetic

mean
43,473
9,572

SD
79,960
23,859.

mean
45,155
9,653

SD
83575
23814

5.2

10.4

5.1

9.7

variable

Val

Admit weekday

1
2
3
4
5
6
7
American
indian/eskimo
Asian or pacific
islander
Black
White
Other

RACE

Real

Synthetic

n
8,659
8,604
8,053
7,963
7,400
4,717
4,604
129

%
17.3
17.2
16.1
15.9
14.8
9.4
9.2
0.3

n
9,189
7,918
7,749
8,317
7,353
4,874
4,600
108

%
18.4
15.8
15.5
16.6
14.7
9.7
9.2
0.2

1,026

2.1

980

2.0

6,585
31,389
10,865

13.2
62.8
21.7

6,321
31,118
11,472

12.6
62.2
22.9

Table 4c: Texas - population statistics - example numeric and categorical variables
Numeric variables
variable

Real

Categorical variables

Synthetic

mean

SD

mean

SD

Tumor size

96.6

258.3

88.7

246.3

# in-situ
malignant

1.4

0.6

1.3

0.6

variable

Val

sex

Female
Male
Grade I

grade

Grade II
Grade III
Grade IV

Real
n
99,286
714
20,060
39,519
30.462
901

Synthetic
%
99.3
0.7
22.1
43.5
33.5
1.0

n
99,361
639
20,723
40,378
30,428
801

%
99.4
0.6
22.4
43.7
33.0
0.9

Table 4d: BREAST - population statistics - example numeric and categorical variables (sample size reduced from
1,500,000 to 100,000).
We ran our univariate analysis across all variables in each dataset, comparing marginal distributions between real
and synthetic. Given limited space we will display here a few selected variables for each dataset. Note that some
variables have non-standard distributions causing some visualizations with histograms to have strange artifacts,
however the match between real and synthetic is still maintained.

Figure 9a: DIG - real vs synthetic - marginal distributions for numeric variables: AGE and BMI

21

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 9b: DIG - real vs synthetic - marginal distributions for categorical variables: no. of symptoms and sex
Due to limited space, we are not showing visualizations for all variables; however, for the DIG dataset table 5 lists
most of the relevant numerical metrics:
Variable

KL-Div

Variable

Wass. Dist.

KS-Val

KS-p

Ace inhibitor
Current angina
Death or hosp from WHF
Death?
Digoxin within past week
Dose of digoxin or placebo
Dyspnea on exertion
Dyspnea at rest
EF method
Elevated jugular venus pressure
Etiology of CHF
History of diabetes
History of hypertension
Hosp: any hospitalization
Hosp: cardiovascular disease
Hosp: coronary revascularization
Hosp: digoxin toxicity
Hosp: MI
Hosp: other cardiovascular event
Hosp: respiratory infection
Hosp: stroke
Hosp: supraventricular arrhythmia
Hosp: unstable angina
Hosp: ventricular arrhythmia
Hosp: worsening heart failure
Number of hospitalizations
Number of symptoms
NYHA Functional class
Peripheral edema
Previous MI
Race
Reason for death
Recommended digoxin dose
S3 gallop
Sex
Treatment

0.00030
0.00324
0.00109
0.00266
0.00086
0.00165
0.00547
0.00522
0.00026
0.00243
0.00335
0.00443
0.00139
0.00508
0.00377
0.00041
0.00000
0.00218
0.00158
0.00143
0.00086
0.00166
0.00185
0.00039
0.00052
0.01114
0.00326
0.00012
0.00326
0.00054
0.00041
0.00433
0.00167
0.00302
0.00023
0.00001

Age
Body mass index
Chest x-ray (CT ratio)
Days until 1st hosp
Days until CREV
Days until CVD
Days until death
Days until DIG
Days until DWHF
Days until MI
Days until OCVD
Days until OTH
Days until RINF
Days until STRK
Days until SVA
Days until UANG
Days until VENA
Days until WHF
DBP (mmHg)
Duration of CHF (months)
EF (percent)
Heart Rate (beats/min)
SBP (mmHg)
Serum Cr (mg/dL)
Serum K level

0.0224
0.0220
0.1014
0.1453
0.1071
0.1223
0.0988
0.1016
0.0815
0.1051
0.1184
0.1382
0.1091
0.1065
0.1149
0.1193
0.1024
0.0814
0.0369
0.0181
0.0456
0.0445
0.0693
0.0957
0.0193

0.0127
0.0136
0.0511
0.0648
0.0620
0.0623
0.0585
0.0602
0.0540
0.0612
0.0666
0.0729
0.0637
0.0613
0.0650
0.0650
0.0601
0.0540
0.0158
0.0115
0.0287
0.0318
0.0389
0.0531
0.0178

0.6889
0.5962
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.4063
0.7925
0.0109
0.0033
0.0001
<0.0001
0.3346

Table 5: full univariate metrics for DIG dataset

22

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 9c: NIS - real vs synthetic - marginal distributions for numeric variables: Age and length of stay

Figure 9d: NIS - real vs synthetic - marginal distributions for categorical variables: depression and amputation

Figure 9e: TEXAS - real vs synthetic - marginal distributions for numeric variables

23

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 9f: TEXAS - real vs synthetic - marginal distributions for categorical variables: Race and Severity of Illness

Figure 9g: BREAST - real vs synthetic - marginal distributions for numerical: cs tumor size and survival in months

Figure 9h: BREAST - real vs synthetic - marginal distributions for categorical variables: summary stage and
laterality
In table 6 we show the marginal distribution match metrics; recall that for numeric variables we use the
KS-Statistic and for categorical variables we use the KL-divergence, and in both cases a value close to 0.0
reflects a good match in distributions:

24

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Dataset
DIG
DIG
DIG
DIG
NIS
NIS
NIS
NIS
TEXAS
TEXAS
TEXAS
TEXAS
BREAST
BREAST
BREAST
BREAST

Variable
AGE
BMI
Num of Symptoms
SEX
Age
Length of stay
Depression
Major Amputation
Total charges
Length of stay
Race
Severity of illness
CS tumor size
Survival months
Summary stage
laterality

Metric
KS-Stat
KS-Stat
KL-Div
KL-Div
KS-Stat
KS-Stat
KL-Div
KL-Div
KS-Stat
KS-Stat
KL-Div
KL-Div
KS-Stat
KS-Stat
KL-Div
KL-Div

Value
0.0082
0.0156
0.0051
0.0004
0.0095
0.0174
0.0001
<0.0001
0.0160
0.0209
0.0008
0.0003
0.0128
0.0082
0.0006
0.0002

Table 6: univariate distribution metrics
Next, we compute pairwise correlations between variables and plot that as a heatmap, where the strength of the
correlation is color-coded with dark blue representing low correlation and red representing strong correlation:

Figure 10a: real vs synthetic - DIG - pairwise correlations; PCD-L1 = 0.0153

25

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 10b: real vs synthetic - NIS - pairwise correlations; PCD-L1 = 0.0071

Figure 10c: real vs synthetic - TEXAS - pairwise correlations; PCD-L1 = 0.0056

Figure 10d: real vs synthetic - BREAST - pairwise correlations; PCD-L1 = 0.0044
Note how the heatmaps in this case are quite similar to each other, reflecting the fact that the synthetic data
maintains the pairwise correlations that exist in the original DIG dataset.
The next set of statistical fidelity metrics examine the multivariate distribution match between real and synthetic
data. Concretely, in our experiments we performed this analysis for each dataset using the following: UMAP
visualization, predictive performance of ML models, discriminator AUC and pMSE.
We computed the UMAP dimensionality reduction as a visual aid, comparing real to synthetic data, as shown in
figures 11a-11d:

26

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 11a: DIG - UMAP dimensionality reduction - real vs synthetic

Figure 11b: NIS - UMAP dimensionality reduction - real vs synthetic

Figure 11c: TEXAS - UMAP dimensionality reduction - real vs synthetic

Figure 11d: BREAST - UMAP dimensionality reduction - real vs synthetic

27

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

This UMAP visualization demonstrates the match in coverage between real and synthetic, across all clusters of
patient records, even for those who represent rare cohorts.
To further evaluate nonlinear multivariate statistical fidelity, for each dataset we trained a machine learning model
(using gradient boosted trees) to predict an outcome of choice from the dataset, using selected predictors from
the data. We trained this model on 80% of the real data and left 20% of the data for validation. We then trained a
model on the synthetic data and validated its performance against the same validation set (20% of the real data).
We repeated this 5 times, each time generating a different synthetic dataset (using random seeds) and measured
the resulting metrics for each, reporting the mean and standard deviation. We also computed the feature
importance of each model (using SHAP values) and compared the top-ranking features for the model trained on
real data vs the model trained on synthetic data. This is demonstrated in figures 12a-12j:

Figures 12a and 12b: DIG - predicting â€œhosp. for worsening heart failureâ€ (left) and â€œall-cause mortalityâ€ (right)

Figure 12c: DIG - feature importance (SHAP) for â€œhosp. for worsening heart failure.â€ nDCG = 0.973

28

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 12d: DIG - feature importance (SHAP) for â€œall-cause mortalityâ€ - real vs synthetic. nDCG = 0.947

Figures 12e and 12f: NIS - predicting â€œmajor amputationâ€ and feature importance (nDCG = 0.9868)

Figures 12g and 12h: TEXAS - â€œillness severityâ€ and feature importance (nDCG=0.9819) real vs synthetic

29

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figures 12i and 12j: BREAST - predicting vital status & feature importance real vs synthetic. (nDCG = 0.9969)
Two of our datasets include time-to-event variables, and for those we perform survival analysis using
Kaplan-Meier as shown in figures 13a-b

Figure 13a: DIG - Kaplan Meier analysis for â€œhospitalization for worsening heart failureâ€ - real vs synthetic

Figure 13b: BREAST - Kaplan Meier analysis for vital status - real vs synthetic
As described in 3.5.3, two useful metrics for a match in multivariate statistical properties between real and
synthetic are the discriminator AUC and pMSE. We computed these metrics for our experimental datasets, each
time comparing real to 5 different generated synthetic datasets - the results are shown in table 7:

30

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Dataset
DIG
NIS
TEXAS
BREAST

DISC-AUC
0.6405 Â± 0.0046
0.5554 Â± 0.0092
0.6577 Â± 0.0071
0.5406 Â± 0.0025

pMSE
0.0706 Â± 0.0004
0.0193 Â± 0.0002
0.0369 Â± 0.0012
0.1715 Â± 0.0000

Table 7: discriminator AUC and pMSE metrics for all datasets

5.2.2 Privacy
As described in section 4 above, we demonstrate privacy preservation by simulating membership inference and
attribute inference and use distance-to-closest-record (DCR) to demonstrate visually the distance between
records in the real dataset to the closest record in the synthetic dataset, as a copy-protection measure.
In our experiments we implemented a measure of distance between records as described in 3.1. It is useful to
look at the DCR distribution between real and synthetic data, as well as compare this to the distribution of DCR
between real records and real records, as described above. Figures 14a-d show the resulting DCR distributions
for our 4 datasets, both synthetic-to-real (green) and real-to-real (blue):

Figure 14a: DIG - distance to closest record synthetic-to-real (green) vs real-to-real (blue).
DCR disclosure risk = 0.0%

Figure 14b: NIS - distance to closest record synthetic vs real
DCR disclosure risk = 0.258%

31

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 14c: TEXAS - distance to closest record synthetic vs real
DCR disclosure risk = 0.0%

Figure 14d: BREAST - distance to closest record synthetic vs real
DCR disclosure risk = 0.0%
In addition to DCR, we measure in our experiments the likelihood of an adversary to successfully complete an
attribute inference or membership inference attacks.
Figures 15a-d show our results for membership inference

Figure 15a: DIG - membership inference
32

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

Figure 15b: NIS - membership inference

Figure 15c: TEXAS - membership inference

Figure 15d: BREAST - membership inference
Tables 8a-d show our results from the attribute inference attack simulation results:
Disclosure risk

Death

0.035588reference

0.000195

Worsening
heart failure
0.000163

Number of
hospitalizations
0.002216

Number of
symptoms
0.0

Total
0.00718

33

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

paper
conservative
No errors

0.000772
0.000965

0.000647
0.000808

0.008776
0.010970

0.0
0.0

0.028470
0.035588

Table 8a: DIG - attribute inference example attack using quasi-identifiers: age, sex, and race, for the sensitive
variables death, worsening-heart-failure, number of hospitalizations and number of symptoms.
Disclosure risk
reference paper
conservative
No errors

Mortality
0.0
0.0
0.0

Length of Stay
0.003617
0.014955
0.018694

Major Amputation
0.0
0.0
0.0

Smoker
0.000375
0.001552
0.001941

Total
0.005592
0.023122
0.028903

Table 8b: NIS - attribute inference example attack using quasi-identifiers age, gender, race and income quartile,
for the sensitive variables mortality, length of stay, major imputation and smoking status.
Disclosure risk Illness Severity Length of Stay
reference paper
conservative
No errors

0.000257
0.001020
0.001275

0.000297
0.001179
0.001474

Patient Status Risk of Mortality Type of admission
1.6e-5
6.5e-5
8.2e-5

9.9e-5
0.000394
0.000493

0.000320
0.001270
0.001588

Total
0.000608
0.002410
0.003012

Table 8c: TEXAS - attribute inference example attack using quasi-identifiers age, race and ethnicity for the
sensitive variables illness severity, length of stay, patient status, risk of mortality and type of admission.
Disclosure risk
reference paper
conservative
No errors

Vital status
7.5e-6
2.97e-5
3.71e-5

Cause of death
1.81e-7
7.16e-7
8.96e-7

Primary site
2.95e-5
0.000116
0.000146

Tumor size
3.52e-5
0.000139
0.000174

Total
0.000101
0.000401
0.000501

Table 8d: BREAST - attribute inference example attack using quasi-identifiers: age, race and sex for the sensitive
variables vital status, cause of death, tumor size and primary site.

6. Discussion and Analysis
We now discuss our observations from the experimental results for each dataset.

6.1 DIG dataset results analysis
The DIG clinical trial dataset includes 6,800 participant records, each with 71 variables. We trained Syntegraâ€™s
engine on this dataset and generated 25,000 synthetic patient records, then compared the real to synthetic using
our fidelity and privacy evaluation framework.
Analysis of fidelity for individual variable distributions is described in table 4a and 5, and figures 9a and 9b. For
categorical variables the KL-divergence values range from 1e-5 to 0.011, and for numeric variables the
KS-statistic values range from 0.0115 to 0.0729 consistent with good correlation between the real and synthetic
distributions across the board. The pairwise heatmap visualization (figure 10a) demonstrates how the pairwise
correlation in the real dataset is maintained in the synthetic, consistent with the low PCD-L1 value of 0.0153.
In figure 11a we show the 2D UMAP dimensionality reduction for both real and synthetic datasets, demonstrating
broad coverage (fidelity) and diversity (privacy); concretely, we observe that real data is split into various â€œclustersâ€
of participants that are similar to each other (points are close together) and the synthetic points cover the same
cluster areas; nevertheless, the synthetic points are not superimposed directly on the real points, but rather are
â€œnearbyâ€ in the cluster - this points to strong preservation of privacy.
For multivariate fidelity, we trained two machine learning models, based on gradient boosted trees; one to predict
â€œall-cause mortalityâ€ (the primary outcome in the study) and another to predict â€œworsening heart failureâ€, a
secondary outcome that was identified as significant in the study. The ROC curves and the associated AUC-ROC
metric (figures 12a and 12b) demonstrate the ability to train a ML model exclusively from the synthetic data and
achieve comparable results to the model trained on the real data. Interestingly, non-linear predictive models such
as we have built here, were not reported in the original study results, as that technique was not possible with the
technology of the time. Synthetic data can allow novel re-use of earlier clinical trial data in support of precision
medicine. Figures 12c and 12d show the feature importance graphs, based on SHAP values, demonstrating that
not only the predictive models arrive at similar performance, they also utilize the same features for the model in
close to the same order. The feature ranking comparison metric of nDCG for DIG is 0.973 for â€œworsening heart
failureâ€ and 0.947 for â€œall-cause mortalityâ€.
The DIG study includes several time-to-event variables, which allowed us to conduct survival analysis and
compare real to synthetic as shown in figure 13a - the resulting Kaplan Meier survival curves demonstrate similar

34

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

likelihood of being endpoint-free for those treated with digoxin vs the placebo and a similar (low) p-value
consistent with the statistical significance of treatment-related hospitalization for worsening heart failure.
As discussed in 3.5.3 we also measured discriminator AUC and pMSE as additional measures of multivariate
fidelity; for the DIG dataset, the discriminator AUC is at 0.5825 and pMSE is at 0.0664, both reasonably low and
consistent with our expectations for a relatively small dataset. As weâ€™ll see below, larger datasets tend to result in
better values for both discriminator AUC and pMSE.
To demonstrate the privacy of synthetic DIG data, we calculated DCR and created a plot of the distribution of
DCR for every real record against the synthetic dataset, as shown in figure 14a. We observe that the lowest DCR
value is about 12 (out of 71 variables) which demonstrates good separation between real and synthetic;
furthermore, the real-to-real (blue) distribution (removing a comparison of each real record to itself which is, by
definition, zero) is very similar to real-to-synthetic, with small deviation to the right of about 1 DCR. Since there
are no values of DCR=0 there are no copied records and thus our disclosure risk estimate based on DCR=0
records 0%.
We simulated a membership inference attack, the results of which are shown in figure 15a. We observe that for
Hamming distance threshold of 15, the success of membership inference attack has the highest variation, with
precision values ranging from 0.65 to slightly less than 0.5 (worse than random). At a recall level above 50%
(hamming distance threshold of 20) we get low precision equivalent to membership inference disclosure risk
score of 0.28% representing very low risk of disclosure.
Table 8a shows our results of the attribute inference attack simulation, using age, sex and race as
quasi-identifiers, to infer the values of four sensitive attributes. In all scenarios the overall disclosure risk as well
as the disclosure risk for each individual sensitive variable is below the 5% threshold, representing very low
disclosure risk.

6.2 NIS dataset results analysis
The NIS dataset includes 116,009 patient records, each with 31 variables. We trained Syntegraâ€™s engine on this
dataset and generated 200,000 synthetic patient records, then compared the real to synthetic using our fidelity
and privacy evaluation framework.
Analysis of fidelity for individual variable distributions is described in table 4b, and figures 9c and 9d. The metrics
for univariate distributions are low, as expect, both for categorical variables (with KL-divergence values of 0.0001
for â€œdepressionâ€ and 2.6e-5 for â€œMajor amputationâ€), and for numeric variables (with KS-statistic values of 0.0095
for â€œageâ€ and 0.0174 for â€œlength of stayâ€); the pairwise heatmap visualization (figure 10b) demonstrates very good
fidelity in pairwise correlations (although correlations are general low in this dataset), consistent with a PCD-L1
value of 0.0044.
In figure 11b we show the 2D UMAP dimensionality reduction for both real and synthetic datasets, demonstrating
broad coverage (fidelity) and diversity (privacy); as with the DIG dataset, we observe that real data is split into a
large number of â€œclustersâ€ of participants that are similar to each other and the synthetic points cover the same
areas, while not being completely superimposed on the real data but rather being nearby and similar to the real
points.
For multivariate fidelity, we trained a machine learning model, based on gradient boosted trees, to predict â€œmajor
amputationâ€ - one of the primary outcomes of interest in the study. The ROC curves are shown in figure 12e
demonstrating AUC of 0.9128 for real and 0.9124 for synthetic - almost identical. Figure 12f shows the feature
importance graphs, based on SHAP values, with good match in the ranking, and nDCG of 0.947.
Discriminator AUC is at 0.5554 and pMSE is at 0.0193, both very low demonstrating difficulty for a discriminator
model to differentiate between real and synthetic records.
The DCR plot for NIS is shown in figure 14b. We observe that the lowest DCR value is zero, which could be
interpreted as potentially risky. However, as discussed above, observing a very similar distribution for the
real-to-real DCR plot provides the context here - in this dataset, it is quite common to find many records, in the
real dataset, that have duplicate values (DCR=0), and thus itâ€™s not surprising that synthetic records also contain a
similar proportion of such records. Applying our methodology, our estimated disclosure risk due to DCR=0 is
0.258%, which represents very low risk.
From our membership inference attack simulation, shown in figure 15b, we observe that high recall is achieved
quickly and with a threshold of 1 recall above 0.5 is already achieved, resulting in an overall effectiveness score
for membership inference of 1.52%.
Table 8b shows our results of the attribute inference attack simulation, using age, sex, race and income quartile
as quasi-identifiers, to infer the values of four sensitive attributes. In all scenarios the overall disclosure risk as

35

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

well as the disclosure risk for each individual sensitive variable is below the 5% threshold, representing very low
disclosure risk.

6.3 TEXAS dataset results analysis
The TEXAS dataset includes 50,000 patient records, each with 18 variables. We trained Syntegraâ€™s engine on this
dataset and generated 100,000 synthetic patient records, then compared the real to synthetic using our fidelity
and privacy evaluation framework.
Analysis of fidelity for individual variable distributions is described in table 4c, and figures 19e and 9f. The metrics
for univariate distributions are low, as expect, both for categorical variables (with KL-divergence values of 0.0003
for â€œseverity of illnessâ€ and 0.0008 for â€œraceâ€), and for numeric variables (with KS-statistic values of 0.0160 for
â€œtotal chargesâ€ and 0.0209 for â€œlength of stayâ€); the pairwise heatmap visualization (figure 10c) demonstrates very
good fidelity in pairwise correlations (although correlations are general low in this dataset), consistent with a
PCD-L1 value of 0.0044.
In figure 11c we show the 2D UMAP dimensionality reduction for both real and synthetic datasets, demonstrating
broad coverage (fidelity) and diversity (privacy); even more than the NIS or DIG datasets, we observe here that
many small clusters and good coverage by synthetic data points.
For multivariate fidelity, we trained a machine learning model, based on gradient boosted trees, to predict
â€œseverity of illnessâ€. The ROC curves are shown in figure 12g demonstrating AUC of 0.6196 for real and 0.6192
for synthetic - almost identical. We note that in this case the predictive model is not performing very well (at
ROC-AUC of 0.62) but it performs similarly for real and synthetic data, which is the main exploration of our study.
Figure 12h shows the feature importance graphs, based on SHAP values, with good match in the ranking, and
nDCG of 1.0.
Discriminator AUC is at 0.6577 and pMSE is at 0.0369; as with DIG, we see a discriminator can have some but
not great success at discriminating between real and synthetic samples.
The DCR plot for TEXAS is shown in figure 14c. Similar to the NIS dataset, we observe that the lowest DCR value
is zero, but the real-to-real DCR plot shows a similar distribution, and in fact our computed disclosure risk
estimate for DCR=0 records in this case is 0%.
From our membership inference attack simulation, shown in figure 15c, we observe that precision is very close to
0.5, representing low disclosure risk, and the overall membership inference effectiveness score is 4.59%.
Table 8c shows our results of the attribute inference attack simulation, using age, race and ethnicity as
quasi-identifiers, to infer the values of five sensitive attributes. In all scenarios the overall disclosure risk as well
as the disclosure risk for each individual sensitive variable is below the 5% threshold, representing very low
disclosure risk.

6.4 BREAST results analysis
The BREAST dataset includes 1,072,173 patient records, each with 117 variables. We trained Syntegraâ€™s engine
on this dataset and generated 1,500,000 synthetic patient records, then compared the real to synthetic using our
fidelity and privacy evaluation framework.
Analysis of fidelity for individual variable distributions is described in table 4d, and figures 9g and 9h. The metrics
for univariate distributions are low, as expect, both for categorical variables (with KL-divergence values of 0.0006
for â€œsummary stageâ€ and 0.0002 for â€œlateralityâ€), and for numeric variables (with KS-statistic values of 0.0082 for
â€œsurvival monthsâ€ and 0.0128 for â€œCS tumor sizeâ€); the pairwise heatmap visualization (figure 10d) demonstrates
very good fidelity in pairwise correlations, consistent with a PCD-L1 value of 0.0044.
In figure 11d we show the 2D UMAP dimensionality reduction for both real and synthetic datasets, demonstrating
broad coverage (fidelity) and diversity (privacy) across all point clusters, similar to what we observed with other
datasets.
For multivariate fidelity, we trained a machine learning model, based on gradient boosted trees, to predict
â€œseverity of illnessâ€. The ROC curves are shown in figure 12i demonstrating AUC of 0.8899 for real and 0.8902 for
synthetic - almost identical. Figure 12j shows the feature importance graphs, based on SHAP values, with good
match in the ranking, and nDCG of 0.9969.
The BREAST dataset includes several time-to-event variables, which allowed us to conduct survival analysis and
compare real to synthetic as shown in figure 13b - the resulting Kaplan Meier estimator curves demonstrate
similar survival likelihoods for males/females between real and synthetic.
Discriminator AUC is at 0.5406 and pMSE is at 0.1715; as with NIS, we observe that large datasets tend to result
in good discriminator AUC values (close to 0.5) reflecting difficulty of the discriminator to distinguish between real
and synthetic data.

36

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

The DCR plot for BREAST is shown in figure 14d. We observe that the lowest DCR value is zero, but for a very
small number of records. Our computed risk of disclosure for records with DCR=0 here is 0%.
From our membership inference attack simulation, shown in figure 15d, we observe that precision is very close to
0.5, representing low disclosure risk, and the overall membership inference effectiveness score is 2.27%.
Table 8d shows our results of the attribute inference attack simulation, using age, race and sex as
quasi-identifiers, to infer the values of four sensitive attributes. In all scenarios the overall disclosure risk as well
as the disclosure risk for each individual sensitive variable is below the 0.05 threshold.

7. Conclusions
For medical data to drive innovation, PII must be removed to maintain patient privacy, at a minimum.
Unfortunately, this is no longer adequate for widespread data sharing - beyond limited access to certified faculty
investigators within academic institutions, such as between academic institutions and commercial third parties
where therapies are most likely to be developed, and for the most sensitive variables. Despite best practices for
limiting access, terms of use agreements, and other ways to assure compliance, it is widely recognized that
de-identified data can be re-identified using techniques such as membership or inference attacks. Outside the US,
where GDPR applies, even a de-identified or pseudo-anonymized dataset cannot be shared. A purely synthetic
dataset, however, since it contains no actual patient data, is not subject to GDPR regulations.
Synthetic data has been proposed as a method which allows low-burden access to medical data, such that
disclosure risk is reduced or eliminated. There is a range of methods that have been proposed by which to create
synthetic data starting from a real dataset (as opposed to simulated or artificially constructed datasets based on
rules). Regardless of the method, for widespread adoption, an acceptable level of fidelity and privacy must be
obtained. In this paper, we have described a suite of metrics to assess a) the statistical fidelity of synthetic data as
compared to the original data, and b) the disclosure risk or risk of re-identification. We further demonstrated our
experimental results on four different datasets using Syntegraâ€™s Medical Mind synthetic data engine.
Other novel methods of testing privacy can be considered, such as making a synthetic dataset openly accessible
to Kaggle or other crowd-sourced competitions, with a cash prize for anyone who can â€œhackâ€ their way into
exposing information about the real data that was used to generate the synthetic data.
Ultimately, our metrics, taken as a whole in relation to either a specific dataset or the overall process of synthetic
data generation, need to drive a decision as to whether synthetic data may substitute for real world data. That
decision could be anchored in analysis of whether the synthetic data is as good a representation of the real data,
as the real data is representative of the entire population from which the real-world data is sampled. In other
words, in order for insights generated by statistical analysis on the real data to be generalized to a wider group of
patients, it is assumed that the real data is a representative sample of the larger universe of patients. In technical
terms, we know the real data is a sample from an unknown probability distribution, and we expect the synthetic
data to be sampled as near as possible from that same distribution.
Similarly, we believe release of high fidelity synthetic data can dramatically reduce the risk of disclosure,
especially relative to traditional de-identification, but is not required to be 100% perfect privacy in order to be
practically usable. To date, we have been unable to re-identify any real data based on the synthetic version, and
the privacy metrics applied to synthetic data produced by the Syntegra Medical Mind suggest a very low risk of
disclosure.

Once synthetic data is considered an acceptable surrogate for real data, and assuming basic access controls, a
far larger group of researchers can have much quicker and less expensive access to all varieties of healthcare
data. Wider access will accelerate a diverse set of insights and therapies than our current burdensome, and
largely failed, system of data exchange.
Acknowledgments
We want to thank Marlene Grenon, Greg Zahner, Patrick Baier, John Cook and Arthur Copstein for their input and
support in for their insights and assistance in constructing this manuscript, and the whole Syntegra team for their
dedicated work implementing the Syntegra Medical Mind and all these validation metrics.

37

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

References
[1] Bauchner, Howard, et al. â€œData Sharing: An Ethical and Scientific Imperative.â€ JAMA, vol. 315, no. 12, Mar.
2016, p. 1238. DOI.org (Crossref), doi:10.1001/jama.2016.2420.
[2] Rights (OCR), Office for Civil. â€œMethods for De-Identification of PHI.â€ HHS.Gov, 7 Sept. 2012,
https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html.
[3] Narayanan, A., and V. Shmatikov. â€œRobust De-Anonymization of Large Sparse Datasets.â€ 2008 IEEE
Symposium on Security and Privacy (Sp 2008), 2008, pp. 111â€“25. IEEE Xplore, doi:10.1109/SP.2008.33.
[4] Sweeney, Latanya. â€œK-ANONYMITY: A MODEL FOR PROTECTING PRIVACY.â€ International Journal of
Uncertainty, Fuzziness and Knowledge-Based Systems, vol. 10, no. 05, Oct. 2002, pp. 557â€“70. DOI.org
(Crossref), doi:10.1142/S0218488502001648.
[5] Salder, Chris (2020) â€œProtecting Privacy in Data Releasesâ€,
https://www.newamerica.org/oti/reports/primer-disclosure-limitation/
[6] Henriksen-Bulmer, Jane, and Sheridan Jeary. â€œRe-Identification Attacksâ€”A Systematic Literature Review.â€
International Journal of Information Management, vol. 36, no. 6, Dec. 2016, pp. 1184â€“92. DOI.org (Crossref),
doi:10.1016/j.ijinfomgt.2016.08.002.
[7] Acquisti, A., and R. Gross. â€œPredicting Social Security Numbers from Public Data.â€ Proceedings of the National
Academy of Sciences, vol. 106, no. 27, July 2009, pp. 10975â€“80. DOI.org (Crossref),
doi:10.1073/pnas.0904891106.
[8] Nisselson, Evan (2018) â€œDeep learning with synthetic data will democratize the tech industryâ€,
https://techcrunch.com/2018/05/11/deep-learning-with-synthetic-data-will-democratize-the-tech-industry/
[9] Abadie, alberto (2020) â€œUsing Synthetic Controls: Feasibility, Data Requirements, and Methodological
Aspectsâ€, https://www.aeaweb.org/content/file?id=12409
[10] Rubin Donald, (1993) â€œStatistical disclosure limitationâ€,
https://www.scb.se/contentassets/ca21efb41fee47d293bbee5bf7be7fb3/discussion-statistical-disclosure-limitation
2.pdf
[11] Howe, Bill, et al. â€œSynthetic Data for Social Good.â€ ArXiv:1710.08874 [Cs], Oct. 2017. arXiv.org,
http://arxiv.org/abs/1710.08874.
[12] Walonoski, Jason, et al. â€œSynthea: An Approach, Method, and Software Mechanism for Generating Synthetic
Patients and the Synthetic Electronic Health Care Record.â€ Journal of the American Medical Informatics
Association, vol. 25, no. 3, Mar. 2018, pp. 230â€“38. DOI.org (Crossref), doi:10.1093/jamia/ocx079.
[13] Dube, Kudakwashe, and Thomas Gallagher. â€œApproach and Method for Generating Realistic Synthetic
Electronic Healthcare Records for Secondary Use.â€ Foundations of Health Information Engineering and Systems,
edited by Jeremy Gibbons and Wendy MacCaull, Springer, 2014, pp. 69â€“86. Springer Link,
doi:10.1007/978-3-642-53956-5_6.
[14] Stout, D (2018) â€œThe New Synthetic: The Promise of Using Simulated Patients from Real World Data in Life
Sciences Research and Developmentâ€, https://www.virtusa.com/perspectives/whitepaper/the-new-synthetic
[15] Jon Starkweather, PhD (2015) â€œA quick demonstration of the importance of graphing your data: A polite nod
of thanks to F. J. Anscombe.â€, https://it.unt.edu/sites/default/files/ansquart_l_jds_jul2015.pdf
[16] Daniel, Wayne W., and Chad Lee Cross. Biostatistics: A Foundation for Analysis in the Health Sciences.
Eleventh edition, Wiley, 2019.
[17] Goncalves, Andre, et al. â€œGeneration and Evaluation of Synthetic Patient Data.â€ BMC Medical Research
Methodology, vol. 20, no. 1, May 2020, p. 108. BioMed Central, doi:10.1186/s12874-020-00977-1.
[18] Snoke, Joshua, et al. â€œGeneral and Specific Utility Measures for Synthetic Data.â€ Journal of the Royal
Statistical Society: Series A (Statistics in Society), vol. 181, no. 3, June 2018, pp. 663â€“88. DOI.org (Crossref),
doi:10.1111/rssa.12358.
[19] Taub, Jennifer and Elliot, Mark (2019) â€œThe Synthetic Data Challenge.â€,
https://unece.org/fileadmin/DAM/stats/documents/ece/ces/ge.46/2019/mtg1/SDC2019_S3_UK_Synthethic_Data_
Challenge_Elliot_AD.pdf
[20] Carlini, Nicholas, et al. â€œThe Secret Sharer: Evaluating and Testing Unintended Memorization in Neural
Networks.â€ ArXiv:1802.08232 [Cs], July 2019. arXiv.org, http://arxiv.org/abs/1802.08232.
[21] Yan, Chao, et al. â€œGenerating Electronic Health Records with Multiple Data Types and Constraints.â€
ArXiv:2003.07904 [Cs, Stat], Mar. 2020. arXiv.org, http://arxiv.org/abs/2003.07904.
[22] McInnes, Leland, et al. â€œUMAP: Uniform Manifold Approximation and Projection.â€ Journal of Open Source
Software, vol. 3, no. 29, Sept. 2018, p. 861. DOI.org (Crossref), doi:10.21105/joss.00861.
[23] Stadler, Theresa, et al. â€œSynthetic Data -- A Privacy Mirage.â€ ArXiv:2011.07018 [Cs], Dec. 2020. arXiv.org,
http://arxiv.org/abs/2011.07018.

38

Syntegra Â© - Fidelity and Privacy of Synthetic Medical Data

[24] Lundberg, Scott, and Su-In Lee. â€œA Unified Approach to Interpreting Model Predictions.â€ ArXiv:1705.07874
[Cs, Stat], Nov. 2017. arXiv.org, http://arxiv.org/abs/1705.07874.
[25] Tomashchuk, Oleksandr, et al. â€œA Data Utility-Driven Benchmark for De-Identification Methods.â€ Trust, Privacy
and Security in Digital Business, edited by Stefanos Gritzalis et al., Springer International Publishing, 2019, pp.
63â€“77. Springer Link, doi:10.1007/978-3-030-27813-7_5.
[26] Carlini, Nicolas, et al. â€œExtracting Training Data from Large Language Modelsâ€,
https://arxiv.org/pdf/2012.07805.pdf
[27] Emam, Khaled El, et al. â€œEvaluating Identity Disclosure Risk in Fully Synthetic Health Data: Model
Development and Validation.â€ Journal of Medical Internet Research, vol. 22, no. 11, 2020, p. e23139.
www.jmir.org, doi:10.2196/23139.
[28] Friedman, Jerome H. and Steppel, Sam â€œA nonparametric procedure for comparing multivariate point setsâ€,
CGTM No. 153, SLAC Computation Group, Stanford, California, Nov 1974.
https://www.slac.stanford.edu/vault/collvault/greylit/cgtm/CGTM153.pdf
[29] Hassanat, Ahmad Basheer, â€œDimensionality Invariant Similarity Measureâ€, Journal of American Science
2014; https://arxiv.org/abs/1409.0923
[30] J. C. Gower, â€œA General Coefficient of Similarity and Some of Its Propertiesâ€, Biometrics, Vol. 27, No. 4.
(Dec., 1971), pp. 857-871., http://members.cbio.mines-paristech.fr/~jvert/svn/bibli/local/Gower1971general.pdf
[31] â€œThe Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure.â€ New England Journal of
Medicine, vol. 336, no. 8, Feb. 1997, pp. 525â€“33. DOI.org (Crossref), doi:10.1056/NEJM199702203360801.

39

